Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Acrux Limited ( (AU:ACR) ).
Acrux Limited announced a change in the director’s interest, with Ross Dobinson acquiring 571,428 free attaching options. This change reflects the issue of options approved at an Extraordinary General Meeting in February 2025, aligning with the terms for Placement and SPP participants. The announcement indicates a strategic move to incentivize leadership and align interests with stakeholders, potentially impacting the company’s operational dynamics and stakeholder relations.
More about Acrux Limited
Acrux Limited operates in the pharmaceutical industry, focusing on the development and commercialization of pharmaceutical products. The company is known for its innovative drug delivery solutions, particularly in the field of transdermal drug delivery systems.
YTD Price Performance: 33.33%
Average Trading Volume: 1,000
Technical Sentiment Signal: Buy
Current Market Cap: $6.13M
For a thorough assessment of ACR stock, go to TipRanks’ Stock Analysis page.